Edwin Kingsley

653 total citations
25 papers, 301 citations indexed

About

Edwin Kingsley is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Edwin Kingsley has authored 25 papers receiving a total of 301 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 10 papers in Hematology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Edwin Kingsley's work include Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (8 papers) and Acute Myeloid Leukemia Research (5 papers). Edwin Kingsley is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (8 papers) and Acute Myeloid Leukemia Research (5 papers). Edwin Kingsley collaborates with scholars based in United States, China and France. Edwin Kingsley's co-authors include Kathryn S. Kolibaba, David Morgan, Jerry Ping, Maria Delioukina, Radhakrishnan Ramchandren, Nam H. Dang, Nilanjan Ghosh, Mark Knapp, André Goy and Jia Ruan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Edwin Kingsley

23 papers receiving 298 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edwin Kingsley United States 8 155 122 103 98 77 25 301
Alessandro Previtali United States 7 257 1.7× 111 0.9× 84 0.8× 101 1.0× 43 0.6× 18 374
Luca Vincenzo Cappelli Italy 10 101 0.7× 140 1.1× 70 0.7× 70 0.7× 111 1.4× 20 284
Sylvain Garciaz France 11 117 0.8× 69 0.6× 113 1.1× 133 1.4× 52 0.7× 46 324
Qi Gao United States 9 126 0.8× 100 0.8× 118 1.1× 180 1.8× 67 0.9× 30 308
Suzanne Fanning United States 9 183 1.2× 182 1.5× 48 0.5× 65 0.7× 141 1.8× 44 320
Elizabeth Budde United States 9 161 1.0× 63 0.5× 105 1.0× 88 0.9× 38 0.5× 26 275
Sandra Bašić‐Kinda Croatia 11 87 0.6× 85 0.7× 96 0.9× 102 1.0× 93 1.2× 42 277
Andrew Belch Canada 7 203 1.3× 136 1.1× 98 1.0× 51 0.5× 98 1.3× 11 360
Neil Palmisiano United States 13 228 1.5× 128 1.0× 156 1.5× 162 1.7× 54 0.7× 64 491
Taku Tsukamoto Japan 10 116 0.7× 83 0.7× 162 1.6× 99 1.0× 43 0.6× 50 304

Countries citing papers authored by Edwin Kingsley

Since Specialization
Citations

This map shows the geographic impact of Edwin Kingsley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edwin Kingsley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edwin Kingsley more than expected).

Fields of papers citing papers by Edwin Kingsley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edwin Kingsley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edwin Kingsley. The network helps show where Edwin Kingsley may publish in the future.

Co-authorship network of co-authors of Edwin Kingsley

This figure shows the co-authorship network connecting the top 25 collaborators of Edwin Kingsley. A scholar is included among the top collaborators of Edwin Kingsley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edwin Kingsley. Edwin Kingsley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fountzilas, Christos, Chih‐Yi Liao, Daneng Li, et al.. (2025). Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial. ˜The œLancet. Gastroenterology & hepatology. 11(2). 137–149.
2.
Zinzani, Pier Luigi, Anna Maria Frustaci, Mayur Narkhede, et al.. (2025). 436 | UPDATED EFFICACY/SAFETY OF BRUTON TYROSINE KINASE DEGRADER BGB‐16673 IN PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NHL: ONGOING PHASE 1 CaDAnCe‐101 RESULTS. Hematological Oncology. 43(S3). 1 indexed citations
3.
Shadman, Mazyar, Ian W. Flinn, Edwin Kingsley, et al.. (2023). Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies. Blood. 142(Supplement 1). 3279–3279. 1 indexed citations
4.
Kwiatek, Michał, Sebastian Grosicki, Javier López Jiménez, et al.. (2023). ABCL-515 Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL. Clinical Lymphoma Myeloma & Leukemia. 23. S439–S440. 4 indexed citations
5.
Castillo, Jorge J., Edwin Kingsley, Mohit Narang, et al.. (2023). Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States. SHILAP Revista de lepidopterología. 4(1). 301–304. 3 indexed citations
6.
Hollebecque, Antoine, Juanita Lopez, Sarina A. Piha‐Paul, et al.. (2022). 731 A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: interim results of a phase 1 study (SGNB6A-001). Regular and Young Investigator Award Abstracts. A763–A763. 2 indexed citations
7.
Shadman, Mazyar, Ian W. Flinn, Edwin Kingsley, et al.. (2022). PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES. HemaSphere. 6. 1769–1770. 1 indexed citations
8.
Shadman, Mazyar, Ian W. Flinn, Edwin Kingsley, et al.. (2022). Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies. Blood. 140(Supplement 1). 3655–3657. 2 indexed citations
9.
Lyons, Roger M., Mikhail Shtivelband, Edwin Kingsley, et al.. (2021). Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab. Leukemia & lymphoma. 62(6). 1353–1360. 2 indexed citations
10.
Goy, André, Radhakrishnan Ramchandren, Nilanjan Ghosh, et al.. (2019). Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL. Blood. 134(13). 1024–1036. 88 indexed citations
11.
Phillips, Tycel, Paul M. Barr, Steven I. Park, et al.. (2018). A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Investigational New Drugs. 37(2). 297–306. 57 indexed citations
12.
Cross, Chad L., et al.. (2018). Cancer survivorship in hematologic malignancies: Lifestyle changes after diagnosis.. Journal of Clinical Oncology. 36(15_suppl). e22089–e22089. 1 indexed citations
13.
Savona, Michael R., Kathryn S. Kolibaba, Paul Conkling, et al.. (2018). Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies. American Journal of Hematology. 93(10). 1199–1206. 45 indexed citations
14.
15.
Savona, Michael R., Kathryn S. Kolibaba, Paul Conkling, et al.. (2014). CC-486 in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML): Safety, Tolerability, and Response. Blood. 124(21). 4638–4638. 2 indexed citations
16.
Berenson, James R., James Hilger, Ori Yellin, et al.. (2013). A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Annals of Hematology. 93(1). 89–98. 34 indexed citations
17.
Yellin, Ori, James R. Berenson, Ralph V. Boccia, et al.. (2012). A phase I/II trial of melphalan (MEL) combined with panobinostat (PAN) for patients with relapsed or refractory (R/R) multiple myeloma (MM).. Journal of Clinical Oncology. 30(15_suppl). e18558–e18558. 4 indexed citations
18.
Kingsley, Edwin, et al.. (2009). An open-label, multicenter, phase II study of AT-101 in combination with rituximab (R) in patients with untreated, grade 1-2, follicular non-Hodgkin's lymphoma (FL). Journal of Clinical Oncology. 27(15_suppl). 8582–8582. 10 indexed citations
19.
Morgan, Rodman, et al.. (1989). Trisomy 14: A new entity within acute nonlymphocytic leukemia. Cancer Genetics and Cytogenetics. 43(1). 35–38. 14 indexed citations
20.
Kingsley, Edwin & Brian G.M. Durie. (1986). Prolonged survival in patients with treatment‐related leukemia. Scandinavian Journal of Haematology. 37(2). 103–105. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alessandro Previtali Breakdown of academic impact, for papers by Luca Vincenzo Cappelli Breakdown of academic impact, for papers by Sylvain Garciaz Breakdown of academic impact, for papers by Qi Gao Breakdown of academic impact, for papers by Suzanne Fanning Breakdown of academic impact, for papers by Elizabeth Budde Breakdown of academic impact, for papers by Sandra Bašić‐Kinda Breakdown of academic impact, for papers by Andrew Belch Breakdown of academic impact, for papers by Neil Palmisiano Breakdown of academic impact, for papers by Taku Tsukamoto
Rankless by CCL
2026